More competition forecast for Myriad despite strong Q1
This article was originally published in Clinica
Executive Summary
Increasing competition in the BRCA cancer gene testing market has not hit Myraid Genetics too hard – not yet anyway. Its first-quarter results came in well above analyst expectations, with revenues of $202m and earnings of $0.68 per share beating consensus of $168m and $0.46, respectively.